PL3648783T3 - Nowe polinukleotydy kodujące ludzkie białko fkrp - Google Patents

Nowe polinukleotydy kodujące ludzkie białko fkrp

Info

Publication number
PL3648783T3
PL3648783T3 PL18736914.5T PL18736914T PL3648783T3 PL 3648783 T3 PL3648783 T3 PL 3648783T3 PL 18736914 T PL18736914 T PL 18736914T PL 3648783 T3 PL3648783 T3 PL 3648783T3
Authority
PL
Poland
Prior art keywords
polynucleotides encoding
novel polynucleotides
protein
human fkrp
human
Prior art date
Application number
PL18736914.5T
Other languages
English (en)
Inventor
Isabelle Richard
Evelyne GICQUEL-ZOUIDA
William LOSTAL
Original Assignee
Genethon
Universite D'evry Val D'essonne
INSERM (Institut National de la Santé et de la Recherche Médicale)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon, Universite D'evry Val D'essonne, INSERM (Institut National de la Santé et de la Recherche Médicale) filed Critical Genethon
Publication of PL3648783T3 publication Critical patent/PL3648783T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL18736914.5T 2017-07-07 2018-07-06 Nowe polinukleotydy kodujące ludzkie białko fkrp PL3648783T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305894 2017-07-07
PCT/EP2018/068420 WO2019008157A1 (en) 2017-07-07 2018-07-06 NOVEL POLYNUCLEOTIDES ENCODING HUMAN FKRP PROTEIN

Publications (1)

Publication Number Publication Date
PL3648783T3 true PL3648783T3 (pl) 2024-11-18

Family

ID=59363068

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18736914.5T PL3648783T3 (pl) 2017-07-07 2018-07-06 Nowe polinukleotydy kodujące ludzkie białko fkrp

Country Status (9)

Country Link
US (2) US11596698B2 (pl)
EP (2) EP3648783B1 (pl)
JP (1) JP7141417B2 (pl)
CN (1) CN110944656B (pl)
DK (1) DK3648783T3 (pl)
ES (1) ES2986113T3 (pl)
FI (1) FI3648783T3 (pl)
PL (1) PL3648783T3 (pl)
WO (1) WO2019008157A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220042045A1 (en) * 2018-12-21 2022-02-10 Genethon Expression cassettes for gene therapy vectors
EP4031673A1 (en) * 2019-09-19 2022-07-27 Genethon Gene therapy expression system alleviating cardiac toxicity of fkrp
CN115996758A (zh) * 2020-06-19 2023-04-21 吉尼松公司 使sgcg在肌肉和心脏中充分表达的基因治疗表达系统
CN116997658A (zh) * 2020-10-07 2023-11-03 阿斯克肋匹奥生物制药公司 用于治疗包括肢带型2I(LGMD2I)的抗肌萎缩相关糖蛋白紊乱的fukutin相关蛋白(FKRP)的治疗性腺相关病毒递送
US20230374542A1 (en) * 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
WO2022147490A1 (en) * 2021-01-04 2022-07-07 The University Of North Carolina At Chapel Hill Optimized fukutin-related proteins (fkrp) and methods of use
EP4493703A4 (en) * 2022-03-18 2026-08-05 Univ Florida METHODS AND COMPOSITIONS FOR TREATING TMEM43-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2014144907A1 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Methods and compounds for the treatment of dystroglycanopathies
ES2744565T3 (es) * 2014-04-25 2020-02-25 Genethon Tratamiento de la hiperbilirrubinemia
EP3262065B1 (en) 2015-02-27 2024-04-03 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods and compositions for treating dystroglycanopathy disorders

Also Published As

Publication number Publication date
CA3069045A1 (en) 2019-01-10
EP3648783A1 (en) 2020-05-13
EP4450078A2 (en) 2024-10-23
WO2019008157A1 (en) 2019-01-10
CN110944656B (zh) 2024-05-03
US20210338837A1 (en) 2021-11-04
JP7141417B2 (ja) 2022-09-22
JP2020530275A (ja) 2020-10-22
DK3648783T3 (da) 2024-09-09
US12582723B2 (en) 2026-03-24
ES2986113T3 (es) 2024-11-08
EP3648783B1 (en) 2024-09-04
FI3648783T3 (fi) 2024-09-10
US11596698B2 (en) 2023-03-07
US20230321277A1 (en) 2023-10-12
CN110944656A (zh) 2020-03-31
EP4450078A3 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
CA188545S (en) Massage element
CA188544S (en) Massage element
CA188553S (en) Massage element
IL263079A (en) Relaxin-encoding polynucleotides
IL262482A (en) New polypeptides
IL275298B1 (en) Mitochondria-targeted peptides
IL265463A (en) Therapeutic peptides related to mots-c
GB201811817D0 (en) No details
IL284035A (en) RNA encodes a protein
GB201611530D0 (en) Novel polypeptides
GB201700557D0 (en) Novel peptides
SG11202005653RA (en) Novel peptide
IL263292A (en) Protease-resistant mono-lipidated peptides
GB201607534D0 (en) Peptides
GB201707139D0 (en) Polypeptides
ZA201902689B (en) Therapeutic protein
GB201604468D0 (en) Peptides
GB201619652D0 (en) Novel polypeptides
GB2571818B (en) Selecting encoding options
GB201708277D0 (en) A Recombinant protein
SG10201913509YA (en) Therapeutic sall4 peptide
GB201607535D0 (en) Peptides
GB2567835B (en) Selecting encoding options
GB201719520D0 (en) Neuroprotectvie peptide
IL266419A (en) Binding peptides